Skip to main content

Dr. Sara M. Tolaney, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
24
In the NPI registry since
2005
Medicare patients seen, 2024
37

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2002Medical school: University of California, San Francisco School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MA license 223936
  • Internal Medicine Physician
    MA license 223936

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
37
Services billed
104
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes9239

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Verzenio (abemaciclib)14
Letrozole
Other prescribers in Boston, MA
14
Ibrance (palbociclib)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 20 companies reported 114 payments worth $177,137 in total to this clinician.

By company
F. Hoffmann-la Roche AG$29,218
Gilead Sciences, Inc.$24,349
Pfizer Inc.$21,703
Eli Lilly and Company$18,138
AstraZeneca UK Limited$16,003
E.r. Squibb & Sons, L.l.c.$15,816
Daiichi Sankyo Inc.$9,608
Beigene USA, Inc.$8,000
By type
Consulting Fee$149,360
Travel and Lodging$16,347
Compensation for services other than consulting (speaking, faculty)$9,135
Food and Beverage$2,251
Education$43.25

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 2, 2025E.r. Squibb & Sons, L.l.c.
Oct 2, 2025
Consulting Fee$14,067
Jul 2, 2025Gilead Sciences, Inc.
Jul 2, 2025
Consulting Fee
Company’s description;4200483;GTF;11313049
$13,750
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Travel and Lodging
Kadcyla; Perjeta · BioOncology · travel to Munich, Germany
$9,866
Mar 4, 2025Beigene USA, Inc.
Mar 4, 2025
Consulting Fee$8,000
Mar 19, 2025Eli Lilly and Company
Mar 19, 2025
Consulting Fee$6,500
Jun 6, 2025AstraZeneca UK Limited
Jun 6, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$6,150
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Consulting Fee
Kadcyla; Perjeta · BioOncology
$6,150
Nov 17, 2025Pfizer Inc.
Nov 17, 2025
Consulting Fee
TUKYSA · ONCOLOGY
$4,800
Dec 18, 2025Eli Lilly and Company
Dec 18, 2025
Consulting Fee$4,600
Jul 9, 2025Boehringer Ingelheim International GmbH
Jul 9, 2025
Consulting Fee$4,255
All 77 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 22, 2025Beone Medicines USA, Inc.
Dec 22, 2025
Consulting Fee$1,600
Dec 18, 2025Eli Lilly and Company
Dec 18, 2025
Consulting Fee$4,600
Dec 17, 2025Corcept Therapeutics
Dec 17, 2025
Compensation for services other than consulting (speaking, faculty)$4,000
Dec 16, 2025AstraZeneca UK Limited
Dec 16, 2025
Consulting Fee
ENHERTU · Oncology
Company’s descriptionResearch Related Service
$833
Dec 12, 2025E.r. Squibb & Sons, L.l.c.
Dec 12, 2025
Consulting Fee$1,290
Dec 11, 2025Pfizer Inc.
Dec 11, 2025
Consulting Fee
TUKYSA · ONCOLOGY
$3,200
Dec 11, 2025Pfizer Inc.
Dec 11, 2025
Consulting Fee$1,540
Dec 11, 2025Pfizer Inc.
Dec 11, 2025
Consulting Fee
TUKYSA · ONCOLOGY
$800
Dec 10, 2025Pfizer Inc.
Dec 10, 2025
Compensation for services other than consulting (speaking, faculty)
TUKYSA · ONCOLOGY
$1,855
Dec 8, 2025Merck Sharp & Dohme LLC
Dec 8, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a research engagement.
$320
Dec 3, 2025AstraZeneca UK Limited
Dec 3, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$1,028
Dec 3, 2025Merck Sharp & Dohme LLC
Dec 3, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a research engagement.
$960
Nov 25, 2025AstraZeneca Pharmaceuticals LP
Nov 25, 2025
Education
ENHERTU · Oncology · in-kind
Company’s descriptionJournal Article
$43.25
Nov 17, 2025Pfizer Inc.
Nov 17, 2025
Consulting Fee
TUKYSA · ONCOLOGY
$4,800
Nov 17, 2025Pfizer Inc.
Nov 17, 2025
Consulting Fee
TUKYSA · ONCOLOGY
$1,500
Nov 12, 2025Daiichi Sankyo Inc.
Nov 12, 2025
Consulting Fee
Enhertu · ONCOLOGY
$1,370
Nov 12, 2025Daiichi Sankyo Inc.
Nov 12, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$1,250
Nov 12, 2025Daiichi Sankyo Inc.
Nov 12, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$343
Nov 10, 2025AstraZeneca UK Limited
Nov 10, 2025
Travel and Lodging
travel to Berlin, Germany
Company’s descriptionResearch Related Service
$99.87
Nov 7, 2025E.r. Squibb & Sons, L.l.c.
Nov 7, 2025
Travel and Lodging
travel to BOSTON, MA
$85.51
Nov 5, 2025Daiichi Sankyo Inc.
Nov 5, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$1,370
Oct 31, 2025AstraZeneca UK Limited
Oct 31, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$685
Oct 20, 2025F. Hoffmann-la Roche AG
Oct 20, 2025
Consulting Fee
Perjeta · BioOncology
$1,230
Oct 18, 2025Gilead Sciences, Inc.
Oct 18, 2025
Travel and Lodging
Trodelvy · ONC · travel to Foster City, CA · in-kind
Company’s description;4253427;VEM US;11313049
$634
Oct 17, 2025AstraZeneca Pharmaceuticals LP
Oct 17, 2025
Consulting Fee
Truqap · Oncology
$2,460
Oct 9, 2025Jazz Pharmaceuticals Inc.
Oct 9, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$1,674
Oct 8, 2025Daiichi Sankyo Inc.
Oct 8, 2025
Consulting Fee
Enhertu · ONCOLOGY
$1,370
Oct 2, 2025E.r. Squibb & Sons, L.l.c.
Oct 2, 2025
Consulting Fee$14,067
Sep 23, 2025Eli Lilly and Company
Sep 23, 2025
Consulting Fee$900
Sep 22, 2025Genentech, Inc.
Sep 22, 2025
Consulting Fee$1,640
Sep 11, 2025Gilead Sciences, Inc.
Sep 11, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4147842;VEM US;11313049
$2,480
Sep 3, 2025E.r. Squibb & Sons, L.l.c.
Sep 3, 2025
Travel and Lodging
travel to Boston, MA
$37.74
Aug 5, 2025Novartis Pharma AG
Aug 5, 2025
Consulting Fee
KISQALI · Oncology
$3,545
Jul 31, 2025Eli Lilly and Company
Jul 31, 2025
Consulting Fee
VERZENIO · Oncology
$1,800
Jul 31, 2025Samsung Bioepis Co., LTD.
Jul 31, 2025
Consulting Fee
E303 · Hematology & Oncology
$520
Jul 30, 2025Merck Sharp & Dohme LLC
Jul 30, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$640
Jul 25, 2025Stemline Therapeutics Inc.
Jul 25, 2025
Consulting Fee
Orserdu · Oncology
$390
Jul 16, 2025Gilead Sciences, Inc.
Jul 16, 2025
Consulting Fee
Company’s description;4280026;GTF;11313049
$3,810
Jul 9, 2025Boehringer Ingelheim International GmbH
Jul 9, 2025
Consulting Fee$4,255
Jul 2, 2025Gilead Sciences, Inc.
Jul 2, 2025
Consulting Fee
Company’s description;4200483;GTF;11313049
$13,750
Jul 1, 2025F. Hoffmann-la Roche AG
Jul 1, 2025
Consulting Fee
Herceptin; Kadcyla; Perjeta · BioOncology
$1,520
Jul 1, 2025AstraZeneca UK Limited
Jul 1, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$833
Jun 25, 2025AstraZeneca UK Limited
Jun 25, 2025
Travel and Lodging
travel to chicago, IL
Company’s descriptionResearch Related Service
$210
Jun 25, 2025AstraZeneca UK Limited
Jun 25, 2025
Travel and Lodging
travel to chicago, IL
Company’s descriptionResearch Related Service
$82.71
Jun 20, 2025Pfizer Inc.
Jun 20, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$1,800
Jun 19, 2025F. Hoffmann-la Roche AG
Jun 19, 2025
Consulting Fee
Kadcyla; Perjeta · BioOncology
$3,280
Jun 6, 2025AstraZeneca UK Limited
Jun 6, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$6,150
Jun 6, 2025F. Hoffmann-la Roche AG
Jun 6, 2025
Consulting Fee
Perjeta · BioOncology
$2,870
May 29, 2025Gilead Sciences, Inc.
May 29, 2025
Travel and Lodging
travel to Chicago, IL
Company’s description;4280047;GTF;11313049
$270
May 29, 2025Gilead Sciences, Inc.
May 29, 2025
Travel and Lodging
travel to Chicago, IL
Company’s description;4280039;GTF;11313049
$105
May 28, 2025Daiichi Sankyo Inc.
May 28, 2025
Consulting Fee
Enhertu · ONCOLOGY
$2,055
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Travel and Lodging
Kadcyla; Perjeta · BioOncology · travel to Munich, Germany
$9,866
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Consulting Fee
Kadcyla; Perjeta · BioOncology
$6,150
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Compensation for services other than consulting (speaking, faculty)
Kadcyla · BioOncology
$3,280
May 14, 2025Daiichi Sankyo Inc.
May 14, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$1,563
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Travel and Lodging
Kadcyla; Perjeta · BioOncology · travel to Munich, Germany
$446
May 14, 2025F. Hoffmann-la Roche AG
May 14, 2025
Travel and Lodging
Kadcyla; Perjeta · BioOncology · travel to Munich, Germany
$178
May 7, 2025AstraZeneca UK Limited
May 7, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$649
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Consulting Fee$2,880
Apr 18, 2025Eli Lilly and Company
Apr 18, 2025
Travel and Lodging
travel to VIENNA, Austria
$4,236
Apr 18, 2025Eli Lilly and Company
Apr 18, 2025
Travel and Lodging
travel to VIENNA, Austria
$72.12
Apr 18, 2025Eli Lilly and Company
Apr 18, 2025
Travel and Lodging
travel to VIENNA, Austria
$25.00
Apr 1, 2025F. Hoffmann-la Roche AG
Apr 1, 2025
Consulting Fee
Herceptin; Kadcyla; Perjeta · BioOncology
$380
Mar 19, 2025Eli Lilly and Company
Mar 19, 2025
Consulting Fee$6,500
Mar 14, 2025Stemline Therapeutics Inc.
Mar 14, 2025
Consulting Fee
Orserdu · Oncology
$780
Mar 7, 2025AstraZeneca UK Limited
Mar 7, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$4,100
Mar 7, 2025Novartis Pharmaceuticals Corporation
Mar 7, 2025
Consulting Fee
KISQALI · Oncology
$2,550
Mar 4, 2025Beigene USA, Inc.
Mar 4, 2025
Consulting Fee$8,000
Mar 2, 2025AstraZeneca Pharmaceuticals LP
Mar 2, 2025
Consulting Fee
ENHERTU · Oncology
$2,226
Feb 19, 2025Gilead Sciences, Inc.
Feb 19, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;3907981;SAP;11313049
$2,910
Feb 14, 2025Pfizer Inc.
Feb 14, 2025
Consulting Fee$600
Feb 12, 2025Merck Sharp & Dohme LLC
Feb 12, 2025
Consulting Fee$2,240
Feb 3, 2025AstraZeneca UK Limited
Feb 3, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$343
Jan 15, 2025Merck Sharp & Dohme LLC
Jan 15, 2025
Consulting Fee
ONCOLOGY
Company’s descriptionProvided as part of a clinical research engagement.
$915
Jan 13, 2025Pfizer Inc.
Jan 13, 2025
Consulting Fee$4,234
Jan 7, 2025Pfizer Inc.
Jan 7, 2025
Consulting Fee
IBRANCE · ONCOLOGY
$1,260
Jan 6, 2025AstraZeneca UK Limited
Jan 6, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$555

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $3,018,300 in research payments for these studies, mostly to the institutions running them.

  • ATEMPT 2 0
    Genentech, Inc.
  • A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
    AstraZeneca Pharmaceuticals LP
  • A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
    Pfizer Inc.
  • A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
    Jazz Pharmaceuticals Inc.
  • Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
    AstraZeneca Pharmaceuticals LP
  • An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
    Merck Sharp & Dohme LLC
  • Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
    Pfizer Inc.
  • Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
    Eli Lilly and Company · Active, not recruiting · NCT03155997
  • A phase 3, open-label, randomized study of dato-dxd versus investigators choice of chemotherapy in participants with inoperable or metastatic hormone receptor positive, HER2 negative breast cancer who have been treate…
    AstraZeneca Pharmaceuticals LP
  • The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
    Pfizer Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 13, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1962487330. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.